

16 23 5
OFFICIAL

Procter & Gamble - I.P. Division

IMPORTANT CONFIDENTIALITY NOTICE

The documents accompanying this telecopy transmission contain confidential information belonging to the sender which is legally protected. The information is intended only for the use of the individual or entity named below. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this telecopied information is strictly prohibited. If you have received this telecopy in error, please immediately notify us by telephone (collect) to arrange for return of the telecopied document to us.

**FACSIMILE TRANSMITTAL SHEET AND
CERTIFICATE OF TRANSMISSION UNDER 37 CFR 1.8**

FAX RECEIVED

MAR 25 2002


GROUP 1600

TO: T. C. McKenzie - United States Patent and Trademark Office

Fax No. 703-872-9306

Phone No. 703-308-9806

I hereby certify that this correspondence is being facsimile transmitted to the United States Patent and Trademark Office on March 19, 2002, to the above-identified facsimile number.

 (Signature)

FROM: Linda R. Schroer (Typed or printed name of person signing Certificate)

Fax No. 513-622-3300

Phone No. 513-622-2859

Listed below are the item(s) being submitted with this Certificate of Transmission:

- 1) Amendment/Transmittal -1 pg.
- 2) Amendment (includes pages showing changes) - 18 pages.
- 3)
- 4)
- 5)

Number of Pages Including this Page: 20

Inventor(s): Charles R. Degenhardt et al.

S.N.: 09/741,272

Filed: December 19, 2000

Case:

Comments:

THE UNITED STATES PATENT & TRADEMARK OFFICE
RESPONSE/AMENDMENT

Case Docket No. 8371

Box Non Fee Amendment
ASSISTANT COMMISSIONER FOR PATENTS
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an AMENDMENT for the patent application:

Inventor(s): DEGENHARDT et al. Confirmation No. 6508

Serial No.: 09/741,272 Group Art Unit: 1624

Date Filed: December 19, 2000 Examiner: T. C. McKenzie

Title: 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS

1. ☒ No additional fee is known to be required.
2. ☐ The fee has been calculated as shown below:

	(Col. 1)		(Col. 2)	(Col. 3)	OTHER THAN A SMALL ENTITY	
	CLAIMS REMAINING AFTER AMENDMENT		HIGHEST NO. PREVIOUSLY PAID FOR	PRESENT EXTRA*	RATE	FEE
TOTAL	* 19	MINUS	** 20	= 0	x \$18 =	\$0
INDEP.	* 1	MINUS	*** 3	= 0	x \$80 =	\$0
FIRST PRESENTATION OF MULTIPLE DEP. CLAIM					+ \$270 =	\$0
					TOTAL	\$0

* If the entry in Col. 1 is less than the entry in Col. 2, write "0" in Col. 3.

** If the highest number of total claims previously paid for is less than 20, write "20" in this space.

*** If the highest number of independent claims previously paid for is less than 3, write "3" in this space.
The "Highest Number Previously Paid For" (Total or Independent) is the highest number found from the equivalent box in Col. 1 of a prior amendment or the number of claims originally filed.

3. ☐ The Commissioner is hereby petitioned under 37 CFR §1.136(a) to grant any extension of time needed for timely response to the Office Action dated November 6, 2001 in the above-identified application to preserve pendency of said application. The processing fee under 37 CFR §1.17 has been determined as follows: for a - month extension of time.
4. The Commissioner is hereby authorized to charge payment of the following fees associated with this communication or credit any overpayment to Deposit Account No. 16-2480. A duplicate copy of this sheet is attached.
 - a. ☒ Any patent application processing fees under 37 CFR §1.16.
 - b. ☒ Any patent application processing fees under 37 CFR §1.17.
5. The Commissioner is hereby authorized to make any additional copies of this sheet needed to accomplish the purposes provided for herein and to charge any fee for such copies to Deposit Account No. 16-2480.

Kelly L. McDow-Dunham

Kelly L. McDow-Dunham
Attorney or Agent for Applicant(s)
Registration No. 43,787
Tel. No. (513) 622-0159

Date: March 19, 2002

Customer No. 27752

(last revised 12/7/01)

Serial No. 09/741,272
Degenhardt et al.

#63
PS

P&G Case 8371

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the Application of

Degenhardt et al.

Serial No. 09/741,272

Filed December 19, 2000

For 2-SUBSTITUTED HETEROCYCLIC COMPOUNDS

Confirmation No. 6508

Group Art Unit 1624

Examiner: T.C. McKenzie

AMENDMENT UNDER 37 CFR § 1.111

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the Office Action dated December 31, 2001 for the above-identified patent application, please consider the following amendments and remarks.

AMENDMENTS TO THE SPECIFICATION

Please amend the title of the present specification to read as follows:

--SUBSTITUTED PIPERIDINE AMIDES AND METHODS OF THEIR USE --

Please amend page 4, paragraph 3 (lines 9 - 12) of the specification as follows:

B1 "Heteroatom" means an atom selected from the group consisting of sulfur, phosphorous, nitrogen, and oxygen, e.g., in the ring of a heterocyclic group or the chain of a heterogeneous group. Groups containing more than one heteroatom may contain different heteroatoms.

AMENDMENTS TO THE CLAIMS

Please cancel Claims 1, 3, 6, 7, 8, 10, and 12 - 17.

Please amend Claim 2 as follows:

B2 2. The compound of Claim 18, wherein A has 5 to 6 members.

Please amend Claim 4 as follows: